[go: up one dir, main page]

MX2020005344A - Compuestos de pirazolopiridinona. - Google Patents

Compuestos de pirazolopiridinona.

Info

Publication number
MX2020005344A
MX2020005344A MX2020005344A MX2020005344A MX2020005344A MX 2020005344 A MX2020005344 A MX 2020005344A MX 2020005344 A MX2020005344 A MX 2020005344A MX 2020005344 A MX2020005344 A MX 2020005344A MX 2020005344 A MX2020005344 A MX 2020005344A
Authority
MX
Mexico
Prior art keywords
compounds
pyrazolopyridinone
pyrazolopyridinone compounds
fgfr
inhibitors
Prior art date
Application number
MX2020005344A
Other languages
English (en)
Inventor
Haibing Guo
Luoheng Qin
Qian Liu
Zhao- Kui WAN
Wing Shun Cheung
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020005344A publication Critical patent/MX2020005344A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)

Abstract

La invención se refiere a nuevos compuestos de pirazolopiridinona, a composiciones farmaceuticas que comprenden dichos compuestos, a procesos para la preparacion de dichos compuestos y al uso de dichos compuestos como inhibidores de FGFR (receptor del factor de crecimiento fibroblastico) y a su uso en el tratamiento de enfermedades, por ejemplo, el cáncer.
MX2020005344A 2017-11-24 2018-11-23 Compuestos de pirazolopiridinona. MX2020005344A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017112835 2017-11-24
PCT/CN2018/117295 WO2019101182A1 (en) 2017-11-24 2018-11-23 Pyrazolopyridinone compounds

Publications (1)

Publication Number Publication Date
MX2020005344A true MX2020005344A (es) 2020-08-13

Family

ID=66630492

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005344A MX2020005344A (es) 2017-11-24 2018-11-23 Compuestos de pirazolopiridinona.

Country Status (10)

Country Link
US (1) US11691970B2 (es)
EP (1) EP3713941B1 (es)
JP (1) JP7312171B2 (es)
KR (1) KR102763767B1 (es)
CN (1) CN111655690B (es)
AU (1) AU2018370903B2 (es)
BR (1) BR112020010012A2 (es)
ES (1) ES2926518T3 (es)
MX (1) MX2020005344A (es)
WO (1) WO2019101182A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113227100B (zh) * 2018-12-26 2023-05-05 詹森药业有限公司 噻吩并吡啶酮化合物
CN110172062B (zh) * 2019-06-21 2022-01-07 南京药石科技股份有限公司 一种单氟代螺环化合物的合成方法及其中间体
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
CN111454214B (zh) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 一种2-甲氧基1-嘧啶乙胺盐酸盐的合成方法
CN116888127B (zh) * 2021-03-10 2025-09-02 轩竹生物科技股份有限公司 三并环类hpk1抑制剂及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
PT1313734E (pt) * 2000-09-01 2010-02-09 Novartis Vaccines & Diagnostic Derivados aza heterocíclicos e sua utilização terapêutica
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
ATE309996T1 (de) 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
EP1539754A4 (en) * 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
US7838527B2 (en) 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
WO2005046590A2 (en) 2003-11-07 2005-05-26 Chiron Corporation Methods for synthesizing quinolinone compounds
DE102006006072B3 (de) 2006-02-09 2007-08-23 Siemens Ag Verfahren zum Sichern der Authentizität von Nachrichten, die gemäß einem Mobile Internet Protokoll ausgetauscht werden
ATE481406T1 (de) 2006-04-06 2010-10-15 Glaxo Group Ltd Pyrrolochinoxalinonderivate als antibakterielle mittel
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
JP5760085B2 (ja) 2010-08-04 2015-08-05 武田薬品工業株式会社 縮合複素環化合物
MX2013006951A (es) 2010-12-16 2013-10-03 Abbvie Inc Compuestos antivirales.
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
US11384099B2 (en) * 2017-11-24 2022-07-12 Janssen Pharmaceutica Nv Pyrazolopyridinone compounds

Also Published As

Publication number Publication date
AU2018370903B2 (en) 2023-09-21
KR20200092987A (ko) 2020-08-04
JP2021504334A (ja) 2021-02-15
US20210147411A1 (en) 2021-05-20
EP3713941A4 (en) 2021-04-14
CN111655690B (zh) 2023-01-10
AU2018370903A1 (en) 2020-05-14
BR112020010012A2 (pt) 2020-10-13
CN111655690A (zh) 2020-09-11
RU2020120784A (ru) 2021-12-24
KR102763767B1 (ko) 2025-02-05
EP3713941A1 (en) 2020-09-30
ES2926518T3 (es) 2022-10-26
EP3713941B1 (en) 2022-06-22
JP7312171B2 (ja) 2023-07-20
CA3082509A1 (en) 2019-05-31
WO2019101182A1 (en) 2019-05-31
US11691970B2 (en) 2023-07-04

Similar Documents

Publication Publication Date Title
NZ784224A (en) Parp1 inhibitors
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX383140B (es) Heterociclos bicíclicos como inhibidores de receptor del factor de crecimiento de fibroblastos (fgfr4).
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MY199705A (en) Heterocyclic compounds as immunomodulators
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX393494B (es) Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX373150B (es) Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2020005342A (es) Compuestos de pirazolopiridinona.
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
MX2016014436A (es) Derivados de heterociclil-butanamida.
MX2018003563A (es) Nuevos compuestos.
IN2014MU00303A (es)
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途